Beta-glucuronidase (bG) is a potential biomarker for cancer diagnosis and prodrug therapy. The ability to image bG activity in patients would assist in personalized glucuronide prodrug cancer therapy. However, whole-body imaging of bG activity for medical usage is not yet available. Here, we developed a radioactive bG activity-based trapping probe for positron emission tomography (PET). We generated a 124 I-tyramine-conjugated difluoromethylphenol beta-glucuronide probe ( 
Introduction b-Glucuronidase (bG) can catalyze the hydrolysis of b-D-glucuronic acid residues for the breakdown of mucopolysaccharides (e.g., heparan sulfate) in lysosomes (1) . It has been widely used as an attractive enzyme for reporter imaging (2) (3) (4) and cancer prodrug therapies (5) (6) (7) (8) . Several glucuronide prodrugs have been used in antibody-directed enzyme prodrug therapy (ADEPT; refs. 9-11) and gene-directed enzyme prodrug therapy (GDEPT; refs. 6, 12, 13) as well as directly in prodrug monotherapy, which relies on the elevated levels of bG found in the tumor microenvironment (14) (15) (16) to selectively convert prodrug into active drug. For instance, Albin and colleagues reported that the level of bG human breast tumors was up to 6-times greater than that in normal tissues (17) . Sperker and colleagues also reported that pancreatic adenocarcinoma exhibited higher bG levels than did normal pancreatic tissue (14) . Furthermore, human tumor xenografts also showed elevated levels of bG, including human breast (MCF-7, BT20, and HS578T), colon (HT29 and SW480), and small-cell lung cancer (OH3 and SW2) cell lines (18) . Elevated levels of bG present in the tumor environment are believed to be due to tumor overexpression (14) and release from necrotic tumor tissues (19) or tumor-infiltrating immune cells (15) . Because bG has been considered as a tumor marker (14, 15, 20) , it would be very useful to image bG activity in vivo to personalize glucuronide prodrug treatment and greatly improve exogenous or endogenous bG-based targeted therapy.
We have previously demonstrated that a fluorescein di-b-D-glucuronide probe (FDGlcU) can be applied for the assessment of bG activity in vivo. However, the fluorescent product FDGlcU rapidly leaked from bG-expressing sites and exhibited poor penetrative properties, limiting imaging to subcutaneous tumors but not deeper tumors (2) . To overcome these problems, we also developed fluorescent glucuronide trapping probes by conjugating a fluorescein isothiocyanate (FITC; lex ¼ 495 nm, lem ¼ 519 nm) and the near infrared dye IR-820 isothiocyanate (NIR; lex ¼ 710 nm, lem ¼ 820 nm) with the difluoromethylphenol betaglucuronide trapping moiety to form FITC-TrapG and NIR-TrapG probes, respectively. Only the highly signal penetrating NIR-TrapG with near infrared spectrum properties can be used in long-term tracking (for about 72 hours) of bG activity in deep liver tissues; the FITCTrapG cannot be. NIR-TrapG is a good probe to monitor the bG activity in small animals (21) but the near infrared fluorescent probes are still not feasible for human use as the large thickness of the human body causes a decrease in fluorescence emission and optical imaging systems for medical usage are not available. Development of a positron emission tomography (PET) glucuronide probe to image bG activity will provide a novel method to allow optimization of the protocols for bG-based personalized cancer therapy. Indeed, we previously described a 124 I-phenolphthalein-glucuronide probe ( 124 I-PTH-G) to image bG activity in vivo by micro-PET (3). The conversion of 124 I-PTH-G by bG caused the in situ precipitation of 124 I-PTH due to its hydrophobic property. However, this probe only allows short-term in vivo imaging (about 3 hours) and may induce carcinogenesis based on a feed study of phenolphthalein in B6C3F 1 mice and F344/N rats (22) .
In the present study, we developed a 124 I-tyraminedifluoromethylphenol-glucuronide probe ( 124 I-TrapG) for imaging bG activity by micro-PET.
124
I-TrapG can be converted by bG to form the quinine methide derivative of 124 I-Trap to quickly react with any nearby nucleophile moiety such as membrane proteins (23) (Fig. 1B) . The specificity of the probe was tested in vitro by incubating a FITCTrapG probe with either CT26/mbG (CT26 cancer cells engineered to express membrane-anchored bG) or parental CT26 cells. The specificity and cytotoxicity of TrapG were also examined by incubating the probe with CT26/ mbG or CT26 cells. For in vivo imaging studies, the 124 I-TrapG was injected into mice bearing both CT26/mbG and parental CT26 tumors to assess intratumoral bG activity by micro-PET. We also examined the biodistribution of 124 I-TrapG in various tissues. To estimate whether TrapG probes can be used to detect endogenous bG activity in vivo, immunodeficient mice bearing Colo205 (human bG high ) and SW620 (human bG low ) tumors were injected with NIR-TrapG for optical imaging. Finally, to evaluate whether the endogenous bG can specifically activate glucuronide prodrugs, mice bearing Colo205 or SW620 tumors were injected with 9-aminocamptothecin glucuronide (9ACG) for bG-mediated prodrug therapy. 9ACG is a water-soluble substrate of bG that displays antineoplastic activity after being hydrolyzed by bG to release a topoisomerase I inhibitor, 9AC. Our results indicate that 124 I-TrapG can systemically image the location and the expression of bG in vitro and in vivo, promoting bG usage as a reporter gene for future clinical therapy protocols.
Materials and Methods

Reagents, cells, and mice
The 9ACG was synthesized as described (24) . D-saccharic acid 1,4-lactone monohydrate (SAL) was purchased from Sigma-Aldrich. We previously generated CT26/mbG cells (2) All these cell lines were maintained in Dulbecco's minimal essential medium (DMEM; SigmaAldrich) supplemented with 10% heat-inactivated bovine calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin at 37 C in an atmosphere of 5% CO 2 . The cell lines were not authenticated by our laboratory. All cell lines were propagated for less than 6 months after resuscitation. Six-to 8-week-old female BALB/cByJNarl and BALB/cAnN.Cg-Foxn1 nu /CrlNarl (BALB/c nude) mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan. Mice were pretreated with 0.2% Lugol solution (Sigma-Aldrich) in their drinking water for 2 days before injection of radioiodinated probes, as previously described (3) to reduce thyroid uptake. All animal experiments were conducted in specific pathogen-free conditions and in accordance with guidelines approved by the Animal Care and Use Committee of the National Yang-Ming University. 
Radioiodination
Liver function evaluation
Groups of BALB/c mice (n ¼ 6) were i.v. injected with PBS or 40 mg/kg TrapG probes. Blood was collected in serum separation 7 days postinjection. Liver injury was assessed by measuring serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL) levels using a Fuji Dri-Chem 3500 biochemistry analyzer (Fujifilm). Whole-body autoradiography in mice Mice (n ¼ 3) were i.v. injected with 1.85 MBq of 131 I-TrapG 3 hours before the mice were sacrificed by means of chloroform inhalation. Animals were dipped into isopentane at liquid nitrogen temperatures and embedded on a cryostat holder (7 Â 5 cm) in 4% carboxylmethylcellulose. The frozen carcass was sliced into 30-mm whole-body sections then attached on microscopic slides. The whole-body sections were applied to an imaging plate (BAS cassette 2040; Fujifilm). After 36 hours of exposure, the phosphor images were acquired with a FLA5000 reader (Fujifilm). C, and sectioned into 5-mm slices. Consecutive sections were either directly placed onto a phosphor imaging plate for autoradiography and detected by Typhoon 9410 phosphorimager (GE Healthcare Life Sciences) or stained with the b-glucuronidase Reporter Gene Staining Kit (Sigma-Aldrich) as previously described (21) .
Reverse transcription polymerase chain reaction SW620 and Colo205 tumor tissue samples from tumorbearing nude mice were snap frozen in liquid nitrogen before grinding the samples into fine powder. Total RNA was extracted by using the NucleoSpin RNA Isolation Kit (MACHEREY-NAGEL) according to the manufacturer's protocol. Five micrograms of total RNA was reverse transcribed by using the SuperScript III RT-PCR system with oligo(dT) primers (Invitrogen). Two microliters of cDNA sample was amplified by PCR and visualized on an agarose gel. The primers 5 0 -TCACC-CAAGAAGCAGCCCTTC-3 0 and 5 0 -CTAGCTGGAAA-TGTTCGCTGC-3 0 for mouse bG; 5 0 -CTGGCGCTGCC-GCAGTTCTTCAA-3 0 and 5 0 -GGTGAAACCCTGCAA-TCGTT-3 0 for human bG; 5 0 -GACCACAGTCCATGC-CATCACT-3 0 and 5 0 -TCCACCACCCTGTTGCTGTAG-3 0 for human GAPDH genes were used in PCR. (1) was prepared as described previously (21) . To prepare of Tyramine-TrapG, tyramine was coupled with compound 1 via an amide linkage to obtain compound 3. The acetyl groups in 3 were removed by treatment with sodium methoxide and the methyl ester was changed to carboxylic acid via methyl trimethylsilanoate in 1 N hydrochloric acid to give compound 5, Tyramine-TrapG. To prepare 131 I-TrapG and 124 I-TrapG, Tyramine-TrapG was labeled with iodine 124 ( 124 I) NaI or 131 I NaI solution and purified on a SepPak PLus C18 cartridge. Details of synthesis are described in Supplementary Methods.
Results
Synthesis of
The specificity of the TrapG probe in bG-expressing cells
To examine whether the activated TrapG probes could be specifically trapped on bG-expressing cells, parental CT26 and CT26/mbG cells (CT26 cells engineered to express membrane-tethered bG on their surface, 93 kDa) were stained with 0.5 mmol/L FITC-TrapG probes in the presence or absence of SAL inhibitors. After washing with PBS, FITC that remained attached to cells was detected on a flow cytometer. As shown in Fig. 2A , CT26/mbG cells were specifically bound to FITC-TrapG probes in the absence of SAL inhibitors as compared with the CT26 cells. Meanwhile, the addition of SAL inhibitors completely suppressed the fluorescence retained by CT26/mbG, indicating that the activation of FITC-TrapG depended on bG activity ( Fig. 2A) . To verify that TrapG could be covalently cross-linked to the cell surface after reaction with bG, FITC-TrapG was added to CT26 or CT26/bG cells and analyzed by anti-FITC Western blot. Compared with the control cells, only CT26/mbG samples showed bands that were detected by anti-FITC antibodies, consistent with covalently cross-linking of FITC to the cell surface proteins as noncovalently bound FITC would dissociate from proteins boiled in reducing SDS-PAGE electrophoresis buffer (Fig. 2B) . We conclude that activated FITCTrap can covalently label bystander nucleophiles on bG-expressing cells.
Toxicity, specificity, and half-life of the TrapG probe
To estimate the cytotoxicity of TrapG to cells, graded concentrations of tyramine-TrapG and BHAMG (an anticancer glucuronide prodrug as positive control) were added to CT26 cells with or without the addition of 2 mg ebG. The incorporation of 3 H-thymidine into cellular DNA was measured as an index of cell viability. Figure  3A shows that 200 mmol/L tyramine-TrapG and BHAMG were not cytotoxic to CT26 cells in absence of bG. In the presence of bG, tyramine-TrapG displayed some toxicity at concentrations greater than about 100 mmol/L, whereas BHAMG was much more cytotoxic with an IC 50 value of about 5 mmol/L. These results indicate that native tyramine-TrapG exhibited low cytotoxicity to cells with or without bG activation.
To examine the specificity of 124 I-TrapG, CT26/mbG or CT26 cells were incubated with graded concentrations of 124 I-TrapG in the presence or absence of the bG inhibitor SAL. In addition, the cells were also incubated with 124 I-TrapG for different time periods. After washing cells with acidic PBS buffer, the radioactivity retained on the cells was measured on a gamma counter. Figures 3A  and B show that addition of SAL completely blocked the radioactivity retained by cells expressing membranetethered bG, showing that the activation of 124 I-TrapG depended on bG activity. In addition, the radioactivity (cpm) retained by CT26/mbG cells after washing with acid PBS was 1.6 to 10.3-fold higher than CT26 cells and was both dose and time dependent (Fig. 3B and 3C ). These results indicate that 124 I-TrapG could be selectively activated by bG, resulting in covalent retention of 124 I-TrapG at bG-expressing cells.
To investigate the toxicity of TrapG probes in vivo, mice were i.v. injected with tyramine-TrapG (40 mg/kg) or PBS. The blood samples were collected and analyzed to evaluate the hematologic parameters 7 days after tyramine-TrapG injection. The liver injury was determined by measuring the serum concentrations of AST, ALT, and TBIL. As shown in Fig. 3D , when compared with the PBStreated mice, the serum levels of AST (P ¼ 0.37), ALT (P ¼ 0.19), and TBIL (P ¼ 0.93) in tyramine-TrapG-treated mice were not significantly increased. These results suggest that tyramine-TrapG did not provoke hepatic toxicity in vivo.
To evaluate the pharmacokinetics of 124 I-TrapG, BALB/ c mice were i.v. injected with 124 I-TrapG and the radioactivity in serum samples collected at defined times was measured on a gamma counter. Figure 4A shows that 124 I-TrapG elimination from the blood followed twophase exponential decay kinetics, with an initial half-life of 7.3 minutes and a terminal half-life of 57.3 minutes. tumors but not CT26 tumors (Fig. 4B) . The region of interest ratios of CT26/mbG to CT26 tumors were 3.3, 21, and 141.4 at 1, 8, and 20 hours, respectively, suggesting that 124 I-TrapG was preferentially hydrolyzed into 124 I-Trap by bG-mediated activation. The radioactivity accumulated in CT26/mbG tumors could last up to 20 hours, indicating that long-term imaging of bG activity can be achieved by using the bG-activated trapping 124 I-TrapG probe. To confirm whether conversion of 124 I-TrapG is bG dependent, mice bearing CT26/mbG and CT26 tumors were i.p. injected with the bG inhibitor SAL before probe injection for PET imaging. Figure 4B shows that SAL completely obstructed the generation and accumulation of radioactivity in CT26/ mbG tumors, suggesting that the conversion of 124 ITrapG to 124 I-Trap was blocked by the suppression of bG activity. A previous study showed that intraperitoneal administration of SAL in mice can prevent CPT-11-induced mucosa damage by inhibiting bacterial bG (26) . Although the pretreatment of SAL hampered the accumulation of cell-associated radioactivity in CT26/mbG tumors (Fig. 4B) , strong abdominal signals were still observed. This result indicates that conversion of the fecal excreted 124 I-TrapG by intestinal bG is not the major source of the abdominal signals. To estimate the colocalization of bG activity and specific 124 I-TrapG retention, CT26 and CT26/mbG tumors were frozen, and sectioned 20 hours after the injection of 124 I-TrapG in tumor-bearing mice. The adjacent tumor sections were either directly exposed to phosphor imaging for autoradiography or stained with X-GlcA substrate to visualize bG activity. Figure 4C shows that autoradiography and bG activity matched in adjacent CT26/ mbG tumor sections. Consistent with the micro-PET analysis, mean radioactivity of CT26/mbG tumors was significantly higher than the CT26 tumors (Fig. 5A) . The accumulation of radioactivity in CT26/mbG tumors were 2.5-, 4.9-, 7.1-, and 9.60fold higher than the CT26 tumor at 1, 8, 20, and 40 hours, respectively. Notably, 15% and 15.7% of the total 131 I-TrapG were found in the gallbladder and urine, respectively, at 1 hour after injection (Fig. 5A) . At 40 hours, 9.3% and 1.3% of the total 131 I-TrapG were found in the gallbladder and urine, respectively. This result suggests that 131 I-TrapG undergoes both renal and biliary excretion. 131 I-TrapG was eliminated rapidly by renal excretion but metabolized slowly by biliary excretion. To confirm this result, whole-mouse sections were detected by autoradiography at 40 hours after probe injection. Figure 5B shows that higher radioactivity accumulated in CT26/ mbG tumors as compared with control CT26 tumors. However, we also found nontargeted 124 I-TrapG in the urine, gallbladder, liver, and intestines, which may be caused by the biliary excretion of 124 I-TrapG into the intestinal tract.
Imaging of bG activity in endogenous bGoverexpressing tumors for targeted 9ACG prodrug therapy
To further investigate whether TrapG probes can be used to image different levels of endogenous bG activity in tumors, mice bearing SW480, HCC36, CL1-5, SW620, Hela, or Colo205 tumors were i.v. injected with NIRTrapG and imaged on an IVIS optical imaging system at 24 hours after injection. As shown in Fig. 6A and Supplementary Fig. S1 , Colo205, CL1-5, and Hela (human bG high ) tumors displayed more fluorescence intensity than SW620, SW480, and HCC36 (human bG low ) tumors. These results suggest that TrapG probes can specifically image the different levels of bG activity in tumors. To investigate whether NIR-TrapG tumor imaging and 9ACG cancer therapy were contributed by increased bG in the tumor microenvironment, the mouse bG expression levels in human SW620 and Colo205 tumors were determined by reverse transcription PCR (RT-PCR). As shown in Fig. 6B , Colo205 tumors displayed elevated mouse bG as compared with the SW620 tumors, indicating that the conversion of TrapG probes and 9ACG prodrugs relies on extracellular bG in the tumor microenvironment. To (Fig. 6C, left) . In contrast, treatment of 9ACG in SW620 tumors did not significantly delay tumor growth (Fig. 6C, right) . These results showed that the therapeutic efficacy of 9ACG prodrug is correlated with the expression levels of endogenous bG, thereby suggesting that the TrapG-based PET imaging system might be used to improve bG-mediated personalized antitumor treatments.
Discussion
We have successfully developed a 124 I-tyraminedifluoromethylphenol-glucuronide probe ( 124 I-TrapG) for in vivo monitoring of bG enzyme activity by micro-PET imaging. The in vitro and in vivo results demonstrated that the 124 I-TrapG probe can be activated by bG to radioactively image bG-expressing cells or tumors. In the cytotoxicity assay, native tyramine-TrapG displayed modest cytotoxicity in the presence of bG. We also found that the therapeutic efficacy of 9ACG prodrug is correlated to the bG levels in tumors that are determined by TrapG imaging. These results indicate that 124 I-TrapG may be a useful probe for the detection of bG activity by PET technology to optimize bG-based targeted therapies in the clinic.
Although 124 I-TrapG can be specifically converted by bG and thereby trapped in bG-expressing tumors, we also observed strong abdominal signals in mice. Two major causes may result in this background signals. First, liver cells can absorb xenobiotic glucuronides from the circulation by organic anion-transporting polypeptides such as estradiol-17-b-D-glucuronide and telmisartan acylglucuronide (27) (28) (29) . Second, glucuronide conjugates can be transported to the intestines via biliary excretion. To diminish this effect, several methods have been used, including depletion of intestinal microbes by antibiotics (30, 31) and inhibition of bacterial bG by chemical inhibitors (32, 33) . Therefore, we treated mice with antibiotics or a bG inhibitor before 124 I-TrapG injection. However, the abdominal signals were not reduced by either elimination of intestinal bacteria (data not show) or inhibition of bacterial bG activity (Fig. 4B) . However, biliary excretion may be reduced by repeated injections of acetaminophen to induce Mrp3 expression and provoke the clearance of glucuronide conjugates through the urinary pathway (34) .
bG is considered as a tumor marker (14, 15, 20) and a prodrug-activating enzyme for cancer prodrug therapies (35, 36) . Connors and Whisson demonstrated that high bG levels present in plasmacytomas were correlated with higher drug sensitivity of the tumors (37) . Indeed, we also found that Colo205 xenografts exhibited high levels of endogenous bG activity based on the imaging results using TrapG probes. Meanwhile, several studies have found that bG accumulates in the necrotic areas of human cancers (14, 18, 38, 39) . In addition, glucuronide conjugates usually exhibit enhanced solubility and decreased cell permeability (3) that greatly increases the utility and specificity of prodrugs or proprobes relying on selective hydrolysis by the bG enzyme. Many bG activity-based prodrugs have been developed for cancer-targeted therapies, including 9ACG (24), BHAMG (40), daunorubicin-GA3 (DNR-GA3; ref. 35) , and glucuronide-conjugated doxorubicin (DOX-GA3, HMR1826; ref. 35) . Thus, the bG activity-based 124 I-TrapG imaging system may provide a powerful tool for tracking tumor associated bG activity by PET imaging to improve bG-based personalized anticancer therapies.
Development of a functional PET probe to image the bG activity in patients would improve bG-based targeted therapy. PET imaging is a sensitive, noninvasive, and clinical used technology for detecting organ function An imaging probe should display low toxicity, high specificity, and strong sensitivity. We previously demonstrated that a near infrared glucuronide trapping probe (NIR-TrapG) is an activity-based probe that allows specific and direct detection of bG activity in preclinical models (21) . In addition, the glucuronide trapping probe did not inhibit bG enzyme activity, which can improve substrate activation, imaging intensity, and might not affect the conversion of bG-based prodrugs (43, 44) . Here, we also verified that TrapG probe exhibits relatively low toxicity (IC 50 > 200 mmol/L). In contrast, FIAU, the substrate for HSV-tk, is much more toxic (IC 50 ¼ 0.073 mmol/L; ref. 45) . Moreover, the glucuronide trapping moiety (difluoromethylphenol) can be conjugated with various probes for multiimaging systems, such as fluorescent dyes (FITC and IR-820) for optical imaging (21) and radioactive isotopes ( The bG activity-based PET probe, 124 I-TrapG, is useful for noninvasive imaging of bG expression in the living body. The 124 I-TrapG possesses several advantages, including (i) the low toxicity of TrapG should allow clinical imaging, (ii) high specificity and signal amplification due to the catalytic hydrolysis of probes by bG, (iii) possibility of generating a wide range of imaging probes by attachment of TrapG groups, and (iv) retention of probes upon bG conversion leading to long-term imaging in vivo. On the basis of these advantages, 124 I-tyramineTrapG may be paired with bG-based prodrugs to generate a personalized therapy system.
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